VAV1, CPTAC-1226 - CPTAC Assay Portal (original) (raw)
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.
VAV1
Protein Sequence hover to view complete sequence
CPTAC-1226: View additional LNPGDIVELTK data
| 10 | 20 | 30 | 40 | 50 |
|---|---|---|---|---|
| MELWRQCTHW | LIQCRVLPPS | HRVTWDGAQV | CELAQALRDG | VLLCQLLNNL |
| 60 | 70 | 80 | 90 | 100 |
| LPHAINLREV | NLRPQMSQFL | CLKNIRTFLS | TCCEKFGLKR | SELFEAFDLF |
| 110 | 120 | 130 | 140 | 150 |
| DVQDFGKVIY | TLSALSWTPI | AQNRGIMPFP | TEEESVGDED | IYSGLSDQID |
| 160 | 170 | 180 | 190 | 200 |
| DTVEEDEDLY | DCVENEEAEG | DEIYEDLMRS | EPVSMPPKMT | EYDKRCCCLR |
| 210 | 220 | 230 | 240 | 250 |
| EIQQTEEKYT | DTLGSIQQHF | LKPLQRFLKP | QDIEIIFINI | EDLLRVHTHF |
| 260 | 270 | 280 | 290 | 300 |
| LKEMKEALGT | PGAANLYQVF | IKYKERFLVY | GRYCSQVESA | SKHLDRVAAA |
| 310 | 320 | 330 | 340 | 350 |
| REDVQMKLEE | CSQRANNGRF | TLRDLLMVPM | QRVLKYHLLL | QELVKHTQEA |
| 360 | 370 | 380 | 390 | 400 |
| MEKENLRLAL | DAMRDLAQCV | NEVKRDNETL | RQITNFQLSI | ENLDQSLAHY |
| 410 | 420 | 430 | 440 | 450 |
| GRPKIDGELK | ITSVERRSKM | DRYAFLLDKA | LLICKRRGDS | YDLKDFVNLH |
| 460 | 470 | 480 | 490 | 500 |
| SFQVRDDSSG | DRDNKKWSHM | FLLIEDQGAQ | GYELFFKTRE | LKKKWMEQFE |
| 510 | 520 | 530 | 540 | 550 |
| MAISNIYPEN | ATANGHDFQM | FSFEETTSCK | ACQMLLRGTF | YQGYRCHRCR |
| 560 | 570 | 580 | 590 | 600 |
| ASAHKECLGR | VPPCGRHGQD | FPGTMKKDKL | HRRAQDKKRN | ELGLPKMEVF |
| 610 | 620 | 630 | 640 | 650 |
| QEYYGLPPPP | GAIGPFLRLN | PGDIVELTKA | EAEQNWWEGR | NTSTNEIGWF |
| 660 | 670 | 680 | 690 | 700 |
| PCNRVKPYVH | GPPQDLSVHL | WYAGPMERAG | AESILANRSD | GTFLVRQRVK |
| 710 | 720 | 730 | 740 | 750 |
| DAAEFAISIK | YNVEVKHIKI | MTAEGLYRIT | EKKAFRGLTE | LVEFYQQNSL |
| 760 | 770 | 780 | 790 | 800 |
| KDCFKSLDTT | LQFPFKEPEK | RTISRPAVGS | TKYFGTAKAR | YDFCARDRSE |
| 810 | 820 | 830 | 840 | 845 |
| LSLKEGDIIK | ILNKKGQQGW | WRGEIYGRVG | WFPANYVEED | YSEYC |
Data source: UniProt
Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs
Uniprot Database Entry PhosphoSitePlus ®
Click a point on a node
to view detailed assay information below
All other points link out to UniProt
Phosphorylation Acetylation Ubiquitylation Other
loading
Assay Details for CPTAC-1226 Collapse assay details
Data source: Panorama
Official Gene Symbol
VAV1
Peptide Sequence
LNPGDIVELTK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
619
Peptide End
629
CPTAC ID
CPTAC-1226
Peptide Molecular Mass
1,197.6605
Species
Homo sapiens (Human)
Assay Type
Direct MRM or SRM
Matrix
Ovarian cancer tumor tissue lysate
Submitting Laboratory
Pacific Northwest National Laboratory
Submitting Lab PI
Tao Liu
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
TSQ Vantage
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Waters nanoACQUITY (Part Number 176016000)
Column Packing
Waters BEH C18, 1.7 um 130 Å (Part Number 186007485)
Column Dimensions
100 um x 100 mm
Flow Rate
0.5 uL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV
| n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y5 (1+) | 16.5 | 6.9 | 5.3 | 36.4 | 8.7 | 8.7 | 40 | 11.1 | 10.2 | 15 | 15 | 15 |
| y8 (1+) | 12.8 | 6.7 | 5.6 | 17.4 | 12.5 | 13 | 21.6 | 14.2 | 14.2 | 15 | 15 | 15 |
| y9 (1+) | 9.1 | 2.6 | 4.8 | 8.2 | 8.6 | 10.7 | 12.2 | 9 | 11.7 | 15 | 15 | 15 |
| sum | 8.5 | 3.3 | 3.6 | 12.6 | 8.6 | 10.5 | 15.2 | 9.2 | 11.1 | 15 | 15 | 15 |
Selectivity
Data source: Panorama
| Slope of Curve Fit for cell line | ||||||
|---|---|---|---|---|---|---|
| fragment_ion | 1 | 2 | 3 | 4 | 5 | 6 |
| y9 (1+) | 0.98 | 0.93 | 0.84 | 0.75 | 1.02 | 0.86 |
| y8 (1+) | 0.95 | 0.98 | 0.8 | 0.74 | 0.96 | 0.88 |
| y5 (1+) | 0.95 | 0.99 | 0.87 | 0.81 | 0.92 | 0.83 |
| sum | 0.97 | 0.95 | 0.84 | 0.76 | 0.99 | 0.86 |
Stability
Data source: Panorama
| Fragment ion / Transition | control_intra_CV | actual_temp_intra_CV | frozen_intra_CV | FTx1_intra_CV | FTx2_intra_CV |
|---|---|---|---|---|---|
| y9 (1+) | 3 | 3.6 | 1.7 | 2.3 | 3.1 |
| y8 (1+) | 3.5 | 5.2 | 5.9 | 2 | 4.9 |
| y5 (1+) | 4 | 6.2 | 1.4 | 8.8 | 1.8 |
| sum | 2.1 | 3.2 | 2.4 | 0.3 | 1.1 |
| Fragment ion / Transition | all_intra_CV | all_inter_CV |
|---|---|---|
| y9 (1+) | 2.9 | 3 |
| y8 (1+) | 4.5 | 4.8 |
| y5 (1+) | 4.7 | 6.7 |
| sum | 2 | 2.9 |
Endogenous
Data source: Panorama
| Fragment ion / Transition | intra_CV | inter_CV | total_CV |
|---|---|---|---|
| y8 (1+) | 51.9 | 71.4 | 88.3 |
| y9 (1+) | 29.4 | 35.9 | 46.4 |
| y5 (1+) | 60.9 | 59.2 | 84.9 |
| sum | 36.7 | 48.8 | 61.1 |
Additional Resources and Comments
Comments
Assay Details for CPTAC-1227 Collapse assay details
Data source: Panorama
Official Gene Symbol
VAV1
Peptide Modified Sequence
YC[+57.0]SQVESASK
Modification Type
Carbamidomethyl Cysteine
Protein - Site of Modification
284
Peptide - Site of Modification
2
Peptide Start
283
Peptide End
292
CPTAC ID
CPTAC-1227
Peptide Molecular Mass
1,157.5023
Species
Homo sapiens (Human)
Assay Type
Direct MRM or SRM
Matrix
Ovarian cancer tumor tissue lysate
Submitting Laboratory
Pacific Northwest National Laboratory
Submitting Lab PI
Tao Liu
Assay Parameters Collapse assay parameters
Data source: Panorama
Instrument
TSQ Vantage
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Waters nanoACQUITY (Part Number 176016000)
Column Packing
Waters BEH C18, 1.7 um 130 Å (Part Number 186007485)
Column Dimensions
100 um x 100 mm
Flow Rate
0.5 uL/min
Assay Multiplexing Expand assay panel
Pacific Northwest National Laboratory-DirectMRM2
Chromatograms
Data source: Panorama
Response Curves
Data source: Panorama
Retrieving Data
Repeatability
Data source: Panorama
| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CV | n= | | | | | | | | | |
| ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- |
| Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High |
| y4 (1+) | 29.3 | 40.2 | 24.8 | 62.1 | 55.7 | 28.1 | 68.7 | 68.7 | 37.5 | 15 | 15 | 15 |
| y5 (1+) | 60.2 | 35.2 | 24 | 51.5 | 41.5 | 30.8 | 79.2 | 54.4 | 39 | 15 | 15 | 15 |
| y8 (1+) | 23.8 | 20.5 | 26.7 | 44.1 | 22.2 | 26.3 | 50.1 | 30.2 | 37.5 | 15 | 15 | 15 |
| sum | 13.9 | 19.3 | 23.2 | 32.2 | 25.2 | 23.3 | 35.1 | 31.7 | 32.9 | 15 | 15 | 15 |
Selectivity
Data source: Panorama
| Slope of Curve Fit for cell line | ||||||
|---|---|---|---|---|---|---|
| fragment_ion | 1 | 2 | 3 | 4 | 5 | 6 |
| y5 (1+) | 0.29 | 0.09 | 0.06 | 0.15 | 0.09 | 0.05 |
| y8 (1+) | 0.08 | 0.08 | 0.09 | 0.16 | 0.08 | 0.09 |
| y4 (1+) | 0.27 | 0.21 | 0.13 | 0.2 | 0.23 | 0.12 |
| sum | 0.14 | 0.09 | 0.09 | 0.16 | 0.09 | 0.09 |
Stability
Data source: Panorama
| Fragment ion / Transition | control_intra_CV | actual_temp_intra_CV | frozen_intra_CV | FTx1_intra_CV | FTx2_intra_CV |
|---|
| Fragment ion / Transition | all_intra_CV | all_inter_CV |
|---|
Endogenous
Data source: Panorama
| Fragment ion / Transition | intra_CV | inter_CV | total_CV |
|---|---|---|---|
| y4 (1+) | 68.3 | 68.2 | 96.5 |
| y5 (1+) | 75.1 | 84.2 | 112.8 |
| y8 (1+) | 106.1 | 112.9 | 154.9 |
| sum | 55.6 | 68.1 | 87.9 |